ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.

作者: Amos Pines , Enrique Z Fisman

DOI: 10.2165/00129784-200303050-00006

关键词:

摘要: ACE inhibitors induce metabolic changes and exert cardioprotective vasoprotective properties, some of which cannot be attributed to their antihypertensive effect per se. Moexipril is an inhibitor with a lipophilicity in the same range as quinapril, benazepril or ramipril, so can readily penetrate lipid membranes thus target tissue addition plasma ACE. Evidence from animal studies shows similar significant (p ≪ 0.05) reductions activity for moexipril quinapril.

参考文章(77)
Maria Olszowska, Roland Asmar, Marta Hlawaty, Wieslawa Tracz, Bernard Goujoun, Fady Sayegh, Joao Maldonado, Michel Jourde, Marc Vincent, Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension. Acta Cardiologica. ,vol. 57, pp. 31- 86 ,(2002)
Björn Dahlöf, Kjell Pennert, Lennart Hansson, Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. American Journal of Hypertension. ,vol. 5, pp. 95- 110 ,(1992) , 10.1093/AJH/5.2.95
Victor J Dzau, Kenneth Bernstein, David Celermajer, Jerome Cohen, Björn Dahlöf, John Deanfield, Javier Diez, Helmut Drexler, Roberto Ferrari, Wiek Van Gilst, Lennart Hansson, Burkhard Hornig, Ahsan Husain, Colin Johnston, Harold Lazar, Eva Lonn, Thomas Lüscher, John Mancini, Albert Mimran, Carl Pepine, Ton Rabelink, Willem Remme, Luis Ruilope, Marcel Ruzicka, Heribert Schunkert, Karl Swedberg, Thomas Unger, Douglas Vaughan, Michael Weber, None, Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovascular Drugs and Therapy. ,vol. 16, pp. 149- 160 ,(2002) , 10.1023/A:1015709617405
Thomas F. Lüscher, Frank Ruschitzka, Georg Noll, Angiotensin Converting Enzyme Inhibitors and Vascular Protection in Hypertension Journal of Cardiovascular Pharmacology. ,vol. 34, pp. S3- S12 ,(1999) , 10.1097/00005344-199908001-00002